Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Open accessThe DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 691
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
ASMBS pediatric metabolic and bariatric surgery guidelines, 2018
Pratt, J. S. A., Browne, A., Browne, N. T., Bruzoni, M., Cohen, M., Desai, A., Inge, T., Linden, B. C., Mattar, S. G., Michalsky, M., et al. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.03.019 · Cited by 555
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Keating, S. E., Hackett, D. A., George, J., & Johnson, N. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.023 · Cited by 537
Bariatric surgery for obesity and metabolic disorders: state of the art
Nguyen, N. T., & Varela, J. E. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.170 · Cited by 505
Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis
Malaguarnera, M., Vacante, M., Antic, T., Giordano, M., Chisari, G., Acquaviva, R., Mastrojeni, S., Malaguarnera, G., Mistretta, A., Li Volti, G., et al. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1887-4 · Cited by 455
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425
Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., & Hekmatdoost, A. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068890 · Cited by 405
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 390
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379
Aller, R., de Luis, D. A., Izaola, O., Conde, R., Sagrado, M. G., Primo, D., Fuente, B. D. L., & González‐Gallego, J. (2011) · PubMed · Cited by 371
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Dufour, J., Oneta, C. M., Gonvers, J., Bihl, F., Cerny, A., Cereda, J., Zala, J., Helbling, B., Steuerwald, M., & Zimmermann, A. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.025 · Cited by 358
Craven, L., Rahman, A., Nair Parvathy, S., Beaton, M., Silverman, J., Qumosani, K., Hramiak, I., Hegele, R., Joy, T., Meddings, J., et al. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000661 · Cited by 342
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Wong, V. W.-S., Wong, G. L.-H., Chan, R. S.-M., Shu, S. S.-T., Cheung, B. H.-K., Li, L. S., Chim, A. M.-L., Chan, C. K.-M., Leung, J. K.-Y., Chu, W. C.-W., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.011 · Cited by 319
Effect of aerobic exercise training dose on liver fat and visceral adiposity
Keating, S. E., Hackett, D. A., Parker, H. M., O’Connor, H. T., Gerofi, J. A., Sainsbury, A., Baker, M. K., Chuter, V. H., Caterson, I. D., George, J., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.022 · Cited by 313
Gao, Y., Zhang, W., Zeng, L.-Q., Bai, H., Li, J., Zhou, J., Zhou, G.-Y., Fang, C.-W., Wang, F., & Qin, X.-J. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101635 · Cited by 291
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
Yaskolka Meir, A., Rinott, E., Tsaban, G., Zelicha, H., Kaplan, A., Rosen, P., Shelef, I., Youngster, I., Shalev, A., Blüher, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323106 · Cited by 287
Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 279
Markova, M., Pivovarova, O., Hornemann, S., Sucher, S., Frahnow, T., Wegner, K., Machann, J., Petzke, K. J., Hierholzer, J., Lichtinghagen, R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.007 · Cited by 273
Schwimmer, J. B., Ugalde-Nicalo, P., Welsh, J. A., Angeles, J. E., Cordero, M., Harlow, K. E., Alazraki, A., Durelle, J., Knight-Scott, J., Newton, K. P., et al. (2019) · JAMA · doi:10.1001/jama.2018.20579 · Cited by 262
Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262
Foster, T., Budoff, M. J., Saab, S., Ahmadi, N., Gordon, C., & Guerci, A. D. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.299 · Cited by 260
Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257
Kobyliak, N., Abenavoli, L., Mykhalchyshyn, G., Kononenko, L., Boccuto, L., Kyriienko, D., & Dynnyk, O. (2018) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.271.kby · Cited by 256
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249
Luukkonen, P. K., Dufour, S., Lyu, K., Zhang, X.-M., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki-Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 249
Xue, L., Deng, Z., Luo, W., He, X., & Chen, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.759306 · Cited by 238
Self-citationPetit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
Properzi, C., O'Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018) · Hepatology · doi:10.1002/hep.30076 · Cited by 227
Flint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16608 · Cited by 224
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.025 · Cited by 220
Watanabe, M., Tozzi, R., Risi, R., Tuccinardi, D., Mariani, S., Basciani, S., Spera, G., Lubrano, C., & Gnessi, L. (2020) · Obesity Reviews · doi:10.1111/obr.13024 · Cited by 215
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213
Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
Glen, J., Floros, L., Day, C., & Pryke, R. (2016) · BMJ · doi:10.1136/bmj.i4428 · Cited by 213
Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1657 · Cited by 197
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
Park, H., Shima, T., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., Itoh, Y., Yoshikawa, T., Fukui, M., Hasegawa, G., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-010-0291-8 · Cited by 195
Iacono, A., Raso, G. M., Canani, R. B., Calignano, A., & Meli, R. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.10.002 · Cited by 192
Taheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 188
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185
Mediterranean diet and metabolic syndrome: An updated systematic review
Esposito, K., Kastorini, C.-M., Panagiotakos, D. B., & Giugliano, D. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9253-9 · Cited by 184
(2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00037 · Cited by 178
Kim, R. G., Loomba, R., Prokop, L. J., & Singh, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.039 · Cited by 174
An update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 174
Mohamad Nor, M. H., Ayob, N., Mokhtar, N. M., Raja Ali, R. A., Tan, G. C., Wong, Z., Shafiee, N. H., Wong, Y. P., Mustangin, M., & Nawawi, K. N. M. (2021) · Nutrients · doi:10.3390/nu13093192 · Cited by 173
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.001 · Cited by 172
Katsagoni, C. N., Papatheodoridis, G. V., Ioannidou, P., Deutsch, M., Alexopoulou, A., Papadopoulos, N., Papageorgiou, M.-V., Fragopoulou, E., & Kontogianni, M. D. (2018) · British Journal of Nutrition · doi:10.1017/s000711451800137x · Cited by 167
Hassani Zadeh, S., Mansoori, A., & Hosseinzadeh, M. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15363 · Cited by 167
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164
Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
Bomhof, M. R., Parnell, J. A., Ramay, H. R., Crotty, P., Rioux, K. P., Probert, C. S., Jayakumar, S., Raman, M., & Reimer, R. A. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1721-2 · Cited by 162
Gaborit, B., Ancel, P., Abdullah, A. E., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01237-2 · Cited by 160
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Francque, S., Laleman, W., Verbeke, L., Steenkiste, C. V., Casteleyn, C. R., Kwanten, W. J., Dyck, C. V., D'Hondt, M., Ramon, A., Vermeulen, W., et al. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.103 · Cited by 147
Takeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K., Misu, H., Ota, T., Nakamura, M., Yamada, K., et al. (2014) · Diabetologia · doi:10.1007/s00125-013-3149-9 · Cited by 146
Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 142
Kannt, A., Wohlfart, P., Madsen, A. N., Veidal, S. S., Feigh, M., & Schmoll, D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15427 · Cited by 139
Exercise-induced myokines in health and metabolic diseases
So, B., Kim, H.-J., Kim, J., & Song, W. (2014) · Integrative Medicine Research · doi:10.1016/j.imr.2014.09.007 · Cited by 135
Sepideh, A., Karim, P., Hossein, A., Leila, R., Hamdollah, M., Mohammad E, G., Mojtaba, S., Mohammad, S., Ghader, G., & Seyed Moayed, A. (2016) · Journal of the American College of Nutrition · doi:10.1080/07315724.2015.1031355 · Cited by 132
Syed‐Abdul, M. M., Parks, E. J., Gaballah, A. H., Bingham, K., Hammoud, G. M., Kemble, G., Buckley, D., McCulloch, W., & Manrique-Acevedo, C. (2020) · Hepatology · doi:10.1002/hep.31000 · Cited by 130
Cheng, R., Wang, L., Le, S., Yang, Y., Zhao, C., Zhang, X., Yang, X., Xu, T., Xu, L., Wiklund, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29968-0 · Cited by 128
Ratziu, V., Sanyal, A. J., Loomba, R., Rinella, M., Harrison, S., Anstee, Q. M., Goodman, Z., Bedossa, P., MacConell, L., Shringarpure, R., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.06.017 · Cited by 126
Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
Oikonomou, D., Georgiopoulos, G., Katsi, V., Kourek, C., Tsioufis, C., Alexopoulou, A., Koutli, E., & Tousoulis, D. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001191 · Cited by 123
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122
Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122
Chen, Y., Feng, R., Yang, X., Dai, J., Huang, M., Ji, X., Li, Y., Okekunle, A. P., Gao, G., Onwuka, J. U., et al. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy358 · Cited by 122
Self-citationMediterranean diet for primary prevention of cardiovascular disease.
Mozaffarian, D. (2013) · PubMed · doi:10.1056/nejmc1306659 · Cited by 121
Brandt, A., Hernández-Arriaga, A. M., Kehm, R., Sánchez, V., Jin, C. J., Nier, A., Baumann, A., Camarinha‐Silva, A., & Bergheim, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-43228-0 · Cited by 119
Lee, J. I., Lee, H. W., Lee, K. S., Lee, H. S., & Park, J.-Y. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000845 · Cited by 119
Liu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 118
Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., Kyriienko, D., Komisarenko, I., & Dynnyk, O. (2018) · Minerva Medica · doi:10.23736/s0026-4806.18.05845-7 · Cited by 108
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., Elnegamy, T. E., Soliman, G. S., & Ibrahim, A. A. (2020) · Medicine · doi:10.1097/md.0000000000019471 · Cited by 108
Depboylu, G. Y., Akbulut, G., Baran, M., & Yılmaz, C. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12872 · Cited by 105
Akuta, N., Watanabe, C., Kawamura, Y., Arase, Y., Saitoh, S., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1019 · Cited by 104
Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Nickel, F., Tapking, C., Benner, L., Sollors, J., Billeter, A. T., Kenngott, H. G., Bokhary, L., Schmid, M., von Frankenberg, M., Fischer, L., et al. (2018) · Obesity Surgery · doi:10.1007/s11695-017-3012-z · Cited by 100
Askari, G., Asgharian, A., Esmailzade, A., Feizi, A., & Mohammadi, V. (2016) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.178533 · Cited by 99
Chen, Y.-S., Liu, H.-M., & Lee, T.-Y. (2019) · Cells · doi:10.3390/cells8030253 · Cited by 98
Self-citationMediterranean diet and NAFLD: what we know and questions that still need to be answered
Plaz Torres, M. C., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, L., & Giannini, E. G. (2019) · Nutrients · doi:10.3390/nu11122971 · Cited by 97
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 97
Siddiqui, M. S., Idowu, M. O., Parmar, D., Borg, B. B., Denham, D., Loo, N. M., Lazas, D., Younes, Z., & Sanyal, A. J. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.051 · Cited by 96
Athyros, V. G., Boutari, C., Stavropoulos, K., Anagnostis, P., Imprialos, K. P., Doumas, M., & Karagiannis, A. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161115666170621082910 · Cited by 94
Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention
O’Gorman, P., Naimimohasses, S., Monaghan, A., Kennedy, M., Melo, A. M., Ní Fhloinn, D., Doherty, D. G., Beddy, P., Finn, S. P., Moore, J. B., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15989 · Cited by 94
Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program
Huber, Y., Pfirrmann, D., Gebhardt, I., Labenz, C., Gehrke, N., Straub, B. K., Ruckes, C., Bantel, H., Belda, E., Clément, K., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15427 · Cited by 93
Biolato, M., Manca, F., Marrone, G., Cefalo, C., Racco, S., Miggiano, G. A. D., Valenza, V., Gasbarrini, A., Miele, L., & Grieco, A. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i4.509 · Cited by 92
Cohen, C. C., Li, K. W., Alazraki, A. L., Beysen, C., Carrier, C., Cleeton, R. L., Dandan, M., Figueroa, J., Knight‐Scott, J., Knott, C. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150996 · Cited by 92
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Nadinskaia, M. Y., Maevskaya, M. V., Ivashkin, V. T., Kodzoeva, K. B., Пирогова, И. Ю., Ev, C., Nersesov, A., Kaibullayeva, J. A., Konysbekova, A., Raissova, A., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i10.959 · Cited by 88
Cho, Y., Rhee, H., Kim, Y., Lee, M., Lee, B., Kang, E. S., Soo, B., Choi, J., & Lee, Y. (2022) · BMC Medicine · doi:10.1186/s12916-022-02288-2 · Cited by 87
Babu, A. F., Csader, S., Männistö, V., Tauriainen, M., Pentikäinen, H., Savonen, K. P., Klåvus, A., Koistinen, V., Hanhineva, K., & Schwab, U. (2022) · Scientific Reports · doi:10.1038/s41598-022-10481-9 · Cited by 85
Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD
Caddeo, A. M., Kowalik, M. A., Serra, M., Runfola, M., Bacci, A., Rapposelli, S., Columbano, A., & Perra, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313105 · Cited by 84
Pérez-Guisado, J., & Muñoz-Serrano, A. (2011) · Journal of Medicinal Food · doi:10.1089/jmf.2011.0075 · Cited by 83
Gastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13907 · Cited by 82
Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81
Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 79
GLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 77
Borém, L. M. A., Neto, J. F. R., Brandi, I. V., Lelis, D. D. F., & Santos, S. H. S. (2018) · Hypertension Research · doi:10.1038/s41440-018-0040-6 · Cited by 73
The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
Doumas, M., Imprialos, K., Dimakopoulou, A., Stavropoulos, K., Binas, A., & Athyros, V. G. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190117114305 · Cited by 70
Brouwers, B., Schrauwen-Hinderling, V. B., Jelenik, T., Gemmink, A., Sparks, L. M., Havekes, B., Bruls, Y., Dahlmans, D., Roden, M., Hesselink, M. K. C., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00266.2017 · Cited by 69
Wong, C., Yaow, C. Y. L., Ng, C. H., Chin, Y. H., Low, Y. F., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.609135 · Cited by 69
Verzijl, C. R. C., Van De Peppel, I. P., Struik, D., & Jonker, J. W. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708898 · Cited by 68
Franco, I., Bianco, A., Mirizzi, A., Campanella, A., Bonfiglio, C., Sorino, P., Notarnicola, M., Tutino, V., Cozzolongo, R., Giannuzzi, V., et al. (2020) · Nutrients · doi:10.3390/nu13010066 · Cited by 68
Crabtree, C. D., Kackley, M. L., Buga, A., Fell, B., LaFountain, R. A., Hyde, P. N., Sapper, T. N., Kraemer, W. J., SCANDLING, D. M., Simonetti, O. P., et al. (2021) · Nutrients · doi:10.3390/nu13030966 · Cited by 60
Jinnouchi, H., Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Suzuki, T., Miyamoto, F., Kajiwara, K., Matsui, K., & Jinnouchi, T. (2015) · Journal of Diabetes Research · doi:10.1155/2015/706416 · Cited by 55
Akbulut, U. E., Işık, İ. A., Atalay, A., Eraslan, A., Durmus, E., Turkmen, S., & Yurttas, A. S. (2021) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2021.1979478 · Cited by 54
Harreiter, J., Just, I., Leutner, M., Bastian, M., Brath, H., Schelkshorn, C., Klepochova, R., Krššák, M., & Kautzky‐Willer, A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14319 · Cited by 53
Cusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
Dwinata, M., Putera, D., Hasan, I., & Raharjo, M. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102173 · Cited by 51
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Akuta, N., Kawamura, Y., Fujiyama, S., Saito, S., Muraishi, N., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Arase, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2005 · Cited by 50
Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
Park, J. S., Seo, J. H., & Youn, H.-S. (2013) · Pediatric Gastroenterology, Hepatology & Nutrition · doi:10.5223/pghn.2013.16.1.22 · Cited by 49
Ali, A., Amin, M. J., Ahmed, M. U., Taj, A., Aasim, M., & Tabrez, E. S. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.38.1.4968 · Cited by 49
Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., et al. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4398-19 · Cited by 48
Chauhan, M., Singh, K., & Thuluvath, P. J. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07317-3 · Cited by 48
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., et al. (2018) · Open Medicine · doi:10.1515/med-2018-0059 · Cited by 48
van der Graaff, D., Kwanten, W. J., Couturier, F., Govaerts, J. S., Verlinden, W., Brosius, I., D'Hondt, M., Driessen, A. L. C., Winter, B. Y. D., Man, J. G. D., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0018-z · Cited by 47
Tobita, H., Yazaki, T., Kataoka, M., Kotani, S., Oka, A., Mishiro, T., Oshima, N., Kawashima, K., Ishimura, N., Naora, K., et al. (2020) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.20-129 · Cited by 46
Akbari, R., Behdarvand, T., Afarin, R., Yaghooti, H., Jalali, M. T., & Mohammadtaghvaei, N. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00524-8 · Cited by 46
Safadi, R., Braun, M., Francis, A., Milgrom, Y., Massarwa, M., Hakimian, D., Hazou, W., Issachar, A., Harpaz, Z., Farbstein, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16664 · Cited by 46
Bariatric Surgery in Cirrhotic Patients: Is It Safe?
Younus, H., Sharma, A., Miquel, R., Quaglia, A., Kanchustambam, S. R., Carswell, K. A., & Patel, A. G. (2020) · Obesity Surgery · doi:10.1007/s11695-019-04214-7 · Cited by 45
Colosimo, S., Ravaioli, F., Petroni, M. L., Brodosi, L., Marchignoli, F., Barbanti, F. A., Sasdelli, A. S., Marchesini, G., & Pironi, L. (2021) · Liver International · doi:10.1111/liv.14799 · Cited by 45
FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model
Kunne, C., Acco, A., Duijst, S., de Waart, D. R., Paulusma, C. C., Gaemers, I. C., & Elferink, R. P. J. O. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.004 · Cited by 44
Muyyarikkandy, M. S., McLeod, M., Maguire, M., Mahar, R., Kattapuram, N., Zhang, C., Surugihalli, C., Muralidaran, V., Vavilikolanu, K., Mathews, C. E., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001495r · Cited by 41
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
Lee, H. Y., Jun, D. W., Kim, H. J., Oh, H., Saeed, W. K., Ahn, H. S., Cheung, R. C., & Nguyen, M. H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.194 · Cited by 40
Anekwe, C. V., Chandrasekaran, P., & Stanford, F. C. (2020) · Cureus · doi:10.7759/cureus.6605 · Cited by 39
Wang, C.-H., Liu, H.-M., Chang, Z., Huang, T., & Lee, T.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157841 · Cited by 37
van der Graaff, D., Chotkoe, S., Winter, B. Y. D., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100412 · Cited by 37
Ritchie, M., Hanouneh, I. A., Noureddin, M., Rolph, T., & Alkhouri, N. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718104 · Cited by 36
Kahl, S., Ofstad, A. P., Zinman, B., Wanner, C., Schüler, E., Sattar, N., Inzucchi, S. E., & Roden, M. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14670 · Cited by 36
Park, J. G., Mok, J. S., Han, Y. I., Park, T. S., Kang, K. W., Choi, C. S., Park, J., & Park, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-40322-1 · Cited by 34
Bravo, M., Raurell, I., Barberá, A., Hide, D., Gil, M., Estrella, F. R., Salcedo, M. T., Augustín, S., Genescà, J., & Martell, M. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048884 · Cited by 34
UDCA for NASH: End of the story?
Haedrich, M., & Dufour, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.009 · Cited by 33
Takahashi, A., Abe, K., Fujita, M., Hayashi, M., Okai, K., & Ohira, H. (2020) · Medicine · doi:10.1097/md.0000000000020399 · Cited by 32
Komorizono, Y., Hosoyamada, K., Imamura, N., Kajiya, S., Hashiguchi, Y., Ueyama, N., Shinmaki, H., Koriyama, N., Tsukasa, M., & Kamada, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14263 · Cited by 30
Beyond weight loss in nonalcoholic fatty liver disease: the role of carbohydrate restriction
Risi, R., Tozzi, R., & Watanabe, M. (2021) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000762 · Cited by 30
Toyoda, Y., Takada, T., Umezawa, M., Tomura, F., Yamanashi, Y., Takeda, K., & Suzuki, H. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00044 · Cited by 28
Dichtel, L. E. (2021) · Hepatology · doi:10.1002/hep.31886 · Cited by 26
Ünsal, İ. Ö., Çalapkulu, M., Sencar, M. E., Çakal, B., & Özbek, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-04361-x · Cited by 25
Jia, G., Han, T., Gao, L., Wang, L., Wang, S.-C., Yang, L., Zhang, J., Guan, Y., Yan, N., Yu, H., et al. (2018) · PubMed · doi:10.3760/cma.j.issn.1007-3418.2018.01.009 · Cited by 22
Trends in statin utilisation in US adults with non‐alcoholic fatty liver disease
Henson, J. B., Patel, Y. A., & Muir, A. J. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16646 · Cited by 21
Tanaka, Y., Ikeda, T., Ogawa, H., & Kamisako, T. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265660 · Cited by 16
Hajifathalian, K., Tafesh, Z., Rosenblatt, R. E., Kumar, S. R., Homan, E. A., Sharaiha, R. Z., Cohen, D. E., Brown, R. S., & Fortune, B. E. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001503 · Cited by 14
Mitrovic, B., Gluvic, Z. M., Μacut, D., et al. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210225110140 · Cited by 14
Semaglutide is safe and efficacious for NASH resolution
Dickson, I. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00396-z · Cited by 7
[Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
Shao, L., Song, Y., & Shi, J. (2021) · PubMed Central · doi:10.3760/cma.j.cn501113-20210430-00215 · Cited by 7
Cited by
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Metadata
- Authors
- Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-16
- Volume
- 13
- Pages
- 1087260-1087260
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W4316363239
- Cited by
- 301
- References
- 177
- FWCI
- 50.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.